At a glance
ClinicalIndex Comparison RecordPhase 2Active· 21 enrolled
Drug / intervention
Decitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Decitabine in Myelofibrosis
In Brief
A Phase 2 clinical trial evaluating Decitabine and Laboratory Biomarker Analysis for Primary Myelofibrosis and Secondary Myelofibrosis. Active but no longer recruiting, targeting 21 participants across 14 sites.
Detailed Summary
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Myelofibrosis, Secondary Myelofibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedNov 2004
Primary CompletionJul 2008
TodayJul 2026
Study CompletionFeb 2027
First PostedNov 9, 2004
Enrollment StartSep 29, 2004
Primary CompletionJul 1, 2008
Study CompletionFeb 22, 2027
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 21.6 years ago
Interventions
Decitabinedrug
Given SC
Laboratory Biomarker Analysisother
Correlative studies